Stockscreener 앱 받기
2.57
4.10%
-0.11
전일 마감가:
$2.68
열려 있는:
$2.72
하루 거래량:
16,485
Relative Volume:
0.13
시가총액:
$7.76M
수익:
$4.88M
순이익/손실:
$-3.66M
주가수익비율:
-1.6748
EPS:
-1.5345
순현금흐름:
$-2.80M
1주 성능:
-5.86%
1개월 성능:
+8.44%
6개월 성능:
-18.41%
1년 성능:
-54.50%
1일 변동 폭
$2.57
$2.74
1주일 범위
$2.5575
$2.7945
52주 변동 폭
$2.11
$8.80
Biomerica Inc Stock (BMRA) Company Profile
명칭
Biomerica Inc
전화
(949) 379-2875
주소
17571 VON KARMAN AVENUE, IRVINE, CA
BMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRA
Biomerica Inc
|
2.57 | 8.09M | 4.88M | -3.66M | -2.80M | -1.5345 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Biomerica Inc Stock (BMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-10 | 개시 | Colliers Securities | Buy |
| 2018-01-04 | 개시 | B. Riley FBR, Inc. | Buy |
Biomerica Inc 주식(BMRA)의 최신 뉴스
Macro Review: Is Biomerica Inc backed by strong institutional buying2025 Breakouts & Breakdowns & Technical Pattern Alert System - baoquankhu1.vn
US-based Biomerica reports net sales of USD 1.21M in Q2 2026 - Medical Buyer
Medical diagnostics firm Biomerica's Q2 revenue falls amid product transition - TradingView — Track All Markets
BIOMERICA INC SEC 10-Q Report - TradingView — Track All Markets
Medicare sets $300 price for IBS test as Biomerica expands AI diet tool - Stock Titan
Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Expands By 123.2% - Defense World
Bullfrog AI Holdings, Inc. (NASDAQ:BFRGW) Short Interest Update - Defense World
Earnings Miss: Is Biomerica Inc stock risky to hold nowPortfolio Update Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
How interest rate cuts could boost Biomerica Inc. stockPortfolio Value Summary & Free Verified High Yield Trade Plans - Улправда
Will Biomerica Inc. stock maintain dividend yield2025 Key Highlights & Expert Approved Momentum Ideas - Улправда
Is Biomerica Inc. stock safe for conservative investorsBuy Signal & Reliable Breakout Forecasts - Улправда
Can Captivision Inc. stock deliver strong Q4 earningsTreasury Yields & Daily Entry Point Trade Alerts - Улправда
How Biomerica Inc. stock responds to policy changesInsider Selling & Weekly Setup with ROI Potential - Улправда
How supply chain issues affect Rain Enhancement Technologies Holdco Inc. Equity Warrant stockQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - Улправда
Why CRVS stock is rated strong buyWeekly Gains Summary & Fast Moving Market Watchlists - Улправда
Will Bulten AB (publ) (3FB) stock return to pre crash levels2025 Dividend Review & Technical Entry and Exit Tips - Улправда
Targets Report: Why Adams Natural Resources Fund Inc. stock remains stableWeekly Investment Recap & Risk Controlled Stock Alerts - Улправда
Is The Vita Coco Company Inc. stock trading at a premium valuationIPO Watch & Safe Capital Growth Plans - Улправда
Zodiac Energy Limited (ZODIAC) Signs Major DealGap Up/Gap Down Analysis & Budget Friendly Trading Strategies - bollywoodhelpline.com
Biomerica Adds Most New Retail Followers Among Biotechs After UAE Nod For Prostate Cancer Screening Test - MSN
Biomerica (NASDAQ:BMRA) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Biomerica (BMRA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Biomerica stock soars after Medicare sets $300 payment rate for IBS test - Investing.com Australia
Medicare to pay $300 for Biomerica’s IBS test starting January 2026 - Investing.com Nigeria
Biomerica Gains Exposure as Distribution Expands in Egypt - StocksToTrade
Biomerica’s Market Presence Expands with Egyptian Drug Authority Authorization - timothysykes.com
Biomerica stock soars after Medicare sets $300 payment rate for IBS test By Investing.com - Investing.com Nigeria
Medicare to pay $300 for Biomerica’s IBS test starting January 2026 By Investing.com - Investing.com South Africa
Biomerica, Inc. Announces Medicare Payment Rate for inFoods® IBS Test Set at $300 Effective January 1, 2026 - Quiver Quantitative
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test - The Manila Times
Biomerica announces CMS Medicare payment rate of $300 for revolutionary Infoods® IBS test - marketscreener.com
Medicare sets $300 price for new food-trigger test to ease IBS pain - Stock Titan
Why Biomerica Inc. stock remains a top recommendationJuly 2025 Analyst Calls & Verified Technical Trade Signals - Улправда
Biomerica stockholders approve key proposals at annual meeting - MSN
Will Biomerica Inc. stock attract more institutional investorsTrade Signal Summary & Expert Verified Movement Alerts - Улправда
Market Review: Is Biomerica Inc. stock a safe haven assetMarket Activity Recap & Scalable Portfolio Growth Methods - Улправда
Will Biomerica Inc. stock recover faster than marketWeekly Market Report & Consistent Income Trade Ideas - Улправда
Can Biomerica Inc. stock maintain operating marginsTrade Volume Report & Stock Portfolio Risk Management - Улправда
What makes Biomerica Inc. stock attractive to growth fundsSmall Cap Stock Opportunities & Minimal Capital Investment - ulpravda.ru
Is Biomerica Inc. stock a safe haven assetJuly 2025 PostEarnings & AI Enhanced Market Trend Forecasts - Улправда
Biomerica Earnings Notes - Trefis
Biomerica (NASDAQ:BMRA) Stock Crosses Below 200-Day Moving Average – What’s Next? - Defense World
Biomerica Stockholders Approve Key Proposals at Annual Meeting - TipRanks
Egyptian drug authority approves Biomerica’s cancer screening portfolio By Investing.com - Investing.com Australia
Biomerica (BMRA) Gains Approval for Rapid Tests in Egypt - GuruFocus
Egyptian drug authority approves Biomerica’s cancer screening portfolio - Investing.com
Biomerica, Inc. Receives Authorization from Egyptian Drug Authority for Comprehensive Cancer and Chronic Disease Screening Portfolio - Quiver Quantitative
Biomerica (NASDAQ:BMRA) versus ProKidney (NASDAQ:PROK) Critical Review - Defense World
Retail Trends: Why Biomerica Inc stock is recommended by analystsRisk Management & Target Return Focused Stock Picks - BỘ NỘI VỤ
Why Biomerica Inc. stock is recommended by analystsJuly 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - Newser
Is Biomerica Inc. stock a good choice for value investorsJuly 2025 Big Picture & AI Enhanced Trading Alerts - Newser
Biomerica Inc (BMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
1.96%
자본화:
|
볼륨(24시간):